辅助生殖中的线粒体靶向治疗策略:挑战与潜在解决方案
线粒体功能关乎卵母细胞能力和早期胚胎发育,其功能障碍与卵巢储备下降、胚胎发育受损及生殖衰老加速相关。辅酶Q10、米托醌、白藜芦醇、雷帕霉素、NAD+前体及线粒体置换技术等在临床前模型中显示潜力,但临床结局异质且常不确定。需更精准的靶点选择、生理相关实验体系及严格安全性评估以推动转化。
要点
- 线粒体功能障碍参与卵巢储备下降、胚胎发育受损和生殖衰老。
- 辅酶Q10、米托醌等药物及线粒体置换技术临床前有潜力但临床结局异质。
- 转化差距源于靶点变异、干预时机不当及临床研究标准化不足。
核心结论
- 线粒体靶向治疗在辅助生殖中临床前有潜力,但临床结局异质且常不确定,需更精准、发育导向且系统验证的方法。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- 线粒体功能障碍 increasingly 被认为是卵巢储备下降、胚胎发育受损和生殖衰老加速的关键因素。
- 药物(辅酶Q10、米托醌、白藜芦醇、雷帕霉素、NAD+前体)及线粒体置换技术(母源纺锤体移植、原核移植)在临床前模型显示潜力,但临床结局异质且常不确定。
临床怎么用
- 应关注定义明确且生理学合理的治疗靶点,并使用生理相关实验系统以提高治疗精准度和疗效。
- 对多效性或可遗传干预需严格评估安全性。
局限性
- 治疗靶点变异、干预时机相对于卵母细胞发育不理想、临床研究把握度不足或标准化不够。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mitochondria are central to oocyte competence and early embryonic development, with roles that extend beyond energy production to include regulation of redox homeostasis, apoptosis and cellular aging. Mitochondrial dysfunction is increasingly recognized as a key contributor to diminished ovarian reserve, impaired embryo development, and accelerated reproductive aging. Mitochondria-targeted therapeutic strategies, including pharmacological approaches such as Coenzyme Q10, mitoquinone, resveratrol, rapamycin, and NAD+ precursors, as well as mitochondrial replacement techniques such as maternal spindle and pronuclear transfer, have shown promise in preclinical models; however, clinical outcomes remain heterogeneous and often inconclusive. This translational gap likely reflects critical limitations, including variability in therapeutic targets, suboptimal timing of intervention relative to oocyte development, and insufficiently powered or standardized clinical studies. Greater emphasis on well-defined, physiologically justified therapeutic targets, along with the use of physiologically relevant experimental systems, may improve therapeutic precision and efficacy. Rigorous evaluation of safety, particularly for interventions with pleiotropic effects or heritable consequences, remains essential. A more targeted, developmentally informed and systematically validated approach is needed to advance mitochondria-based therapies toward meaningful improvements in reproductive outcomes.
引用
- Yildirim RM, Sahin GN, Scott RT, et al. Mitochondria-targeted therapeutic strategies in assisted reproduction: challenges and potential solutions. Hum Reprod. 2026. PMID: 42546117. doi:10.1093/humrep/deag118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。